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RESEARCH ARTICLE
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Abstract
Introduction: This study assessed the hypothesis that circulating human amylin
(amyloid-forming) cross-seeds with amyloid beta (Aβ) in early Alzheimer’s disease (AD).
Methods: Evidence of amylin-AD pathology interaction was tested in brains of 31
familial AD mutation carriers and 20 cognitively unaffected individuals, in cerebrospinal fluid (CSF) (98 diseased and 117 control samples) and in genetic databases.
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1

For functional testing, we genetically manipulated amylin secretion in APP/PS1 and
non-APP/PS1 rats.
Results: Amylin-Aβ cross-seeding was identified in AD brains. High CSF amylin levels were associated with decreased CSF Aβ42 concentrations. AD risk and amylin
gene are not correlated. Suppressed amylin secretion protected APP/PS1 rats against
AD-associated effects. In contrast, hypersecretion or intravenous injection of human
amylin in APP/PS1 rats exacerbated AD-like pathology through disruption of CSF-brain
Aβ exchange and amylin-Aβ cross-seeding.
Discussion: These findings strengthened the hypothesis of circulating amylin-AD interaction and suggest that modulation of blood amylin levels may alter Aβ-related pathology/symptoms.
KEYWORDS

amylin, amyloid, familial Alzheimer’s disease, islet amyloid polypeptide, sporadic Alzheimer’s disease

INTRODUCTION

fluid (CSF)12 could increase the risk for AD. Even if amylin secretion is
normal in AD, amylin may be harmful to the brain by interacting with

Disease course-modifying therapeutic targets remain the highest

Aβ pathology. Importantly, insulin secretion is to some extent modifi-

unmet needs in Alzheimer’s disease (AD),1 a brain disorder that afflicts

able, and therapeutic agents to block amyloidogenicity of circulating

more than 5.7 million Americans of all ages, a number projected to

amylin13 may be a means of reducing amylin–Aβ cross-seeding.

triple by 2050. Given that deterioration of cognition and cerebral accu-

Because individuals with early-onset familial forms of AD will

mulation of amyloid beta (Aβ) and tau tangles are characteristics of AD

develop AD pathology,14 evidence of amylin–Aβ cross-seeding in the

dementia, in brain imaging and at autopsy,2 current therapeutic strate-

brains of persons with familial AD (fAD) could strengthen the hypoth-

gies are aimed at interrupting cerebral Aβ plaque formation. Alterna-

esis of a role of circulating amylin in AD pathology. We therefore

tive approaches may involve modulation of blood levels of proteins that

analyzed brains of individuals inheriting mutations in the amyloid

cross-seed

with Aβ. Recent data from multiple research teams3–8

sug-

precursor protein (APP) and presenilin 1 (PS1) for immunochemical

gest that one potential modifier of AD pathology may be circulating

evidence of amylin interaction with areas of AD-related histopathol-

amylin, an amyloidogenic pancreatic hormone.9

ogy (Aβ and tau deposits). To test whether circulating amylin is involved

The pancreatic hormone amylin (or islet amyloid polypeptide [IAPP])

in early AD pathological processes, we analyzed the amylin–Aβ42

normally participates in the regulation of satiation through signaling

relationship in CSF from humans with AD pathologic change and a

pathways within the hypothalamus.10 Recent analyses of plasma data

diagnosis of mild cognitive impairment (MCI) or dementia, and in

from Alzheimer’s Disease Neuroimaging Initiative and in serum data

CSF from cognitively unimpaired (CU) individuals. To directly address

from the Texas Alzheimer’s Research and Care Consortium identified

the potential for modulation of circulating amylin levels as means to

circulating pancreatic amylin as a mediator of age-specific effects on

alter AD-related pathology/symptoms, we manipulated the pancreatic

dementia severity.8 Brain parenchyma and microvasculature in indi-

secretion of amylin through gene suppression and overexpression in

viduals with late-onset sporadic AD (sAD) have amylin deposits and

APP/PS1 rats and infused human amylin intravenously in APP/PS1 rats.

mixed amylin–Aβ plaques.3–7 Aggregated amylin with similar molecu-

Our work provides a basis for additional studies to validate circulating

lar weights were identified in matched plasma and brain tissues from

amylin as a potential therapeutic target for AD.

humans with sAD3 suggesting that toxic amylin species include circulating aggregated amylin.
Because amylin is co-secreted with insulin,11 conditions with insulin

2

METHODS

dysregulation, such as insulin resistance and type 2 diabetes, may
increase the amount of amylin crossing from blood to the central ner-

Detailed methods are included in Appendix A in supporting informa-

vous system. High circulating amylin levels in plasma and cerebrospinal

tion.
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2.1

Human studies
Research in Context

Institutional review board approval and informed consent were
1. Systematic review: Although the association between

obtained prospectively at the institutions participating in this

dysregulation of circulating amylin (islet amyloid polypep-

study. Formalin fixed and frozen temporal cortex tissue from

tide [IAPP]) and Alzheimer’s disease (AD) pathology is not

31 fAD mutation carriers were provided by the Queen Square

yet as widely studied as other aspects of AD biology, accu-

Brain Bank for Neurological Disorders at UCL Queen Square

mulating evidence from multiple research teams describe

Institute of Neurology (United Kingdom) and King’s College Lon-

amylin–amyloid beta (Aβ) cross-seeding in brains of indi-

don (United Kingdom). Both formalin fixed and frozen tissue

viduals with sporadic AD. One study reported that high

was available for 14 brains. Brain tissue samples from 20 age-

blood amylin and high cerebrospinal fluid (CSF) amylin

matched CU individuals were obtained from the AD Center at

correlate in sporadic AD.

the University of Kentucky (USA). AD Centers at the University

2. Interpretation of results: Early AD processes may affect

of Kentucky, University of Washington (USA), Wake Forest Uni-

the central regulation of pancreatic amylin leading to

versity (USA), and University of Gothenburg (Sweden) provided

abnormal circulating amylin and amylin–Aβ cross-seeding

the CSF samples for this study (98 diseased and 117 control

in the brain.

samples). Details on patients and sample size for each analy-

3. Future directions: This study provides a basis for addi-

sis are summarized in Appendix B, Tables B.1-B.3 in supporting

tional hypothesis-driven research and evidence-based

information.

validation studies to help understand: the triggers of
amylin–Aβ interaction and whether reducing amylin

2.1.1

dyshomeostasis could slow the progression of AD, the

Immunochemical analyses

impact of peripheral amylin dyshomeostasis on Aβ clearance across the blood-brain barrier, and effects of circu-

Frozen and formalin fixed brain tissues were processed as previously

lating amylin levels on CSF–brain Aβ exchange in human

described.3,7 Brain amylin and Aβ concentrations were measured using

AD.

the enzyme-linked immunosorbent assay (ELISA) for amylin (EZHA52K, Millipore) and Aβ42 (KHB3441, Thermo Fisher). Brain amylin
deposition and interaction with AD-related histopathology were
assessed by immunohistochemistry (IHC) and confocal microscopy.
For IHC analysis, the immunoreactivity intensity signals of amylin and

2.2

Animal studies

Aβ were deconvoluted using ImageJ. Details on antibodies, reagents,
and image analysis are included in Appendix A.

This investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the U.S. National Institutes of Health
(NIH Publication No. 85-23, revised 2011) and was approved by

2.1.2

CSF amylin and CSFAβ42 levels

the Institutional Animal Care and Use Committees at University of
Kentucky.

Observer-blind measurement of CSF amylin levels was performed by using amylin ELISA (EIA-AMY; RayBiotech). The
results were communicated to the AD Centers providing the
samples for assessing the relationships with CSF Aβ42 and cog-

2.2.1
Human amylin expression in APP/PS1 and
non-APP/PS1 rats

nitive function of the individuals providing the sample. CSF
Aβ42 levels were measured with the INNO-BIA AlzBio3 mul-

Rats that overexpress (three-fold) human amylin in the pancreas

tiplex assay (FujiRebio) at the AD Centers providing the sam-

(HIP rats) and develop brain amylin pathology6,7,15 were crossed

ples.

with APPSwe /PS1ΔE9 rats (TgF344-19 rats) that develop AD-like
pathology16 to generate APP/PS1/HIP rats (amylin-Aβ model rats).
Because rodent amylin is non-amyloidogenic,9 APP/PS1 littermates

2.1.3

Genomic analysis

served as controls for the amyloidogenic human amylin effects. HIP
and wild-type (WT) rats from the same litters as APP/PS1/HIP and

Databases from the International Genomics of Alzheimer’s Project
(IGAP; n = 17,008 AD cases and n = 13,154 controls) and Healthy Exosomes (HEX; n = 331 AD cases and n = 468 controls) were used to test

APP/PS1 rats were used to assess the effects of brain amylin pathology,
in the absence of APPSwe /PS1ΔE9 mutations. F2 litters were used in
experiments. Male rats were used, because amylin dyshomeostasis

the association of common and rare amylin gene variants with the risk

develops earlier in male (≈12 months) than in female (> 18 months)

for AD.

rats.7
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2.2.2
rats

Suppressed amylin expression in APP/PS1

In fAD brains, amylin immunoreactivity was detected in neuronal
soma (Figures 1F and 1G; arrowheads; 26 of 27 patients) and neuritic plaques (Figure 1H-M, 16 of 27 patients). In some amylin–Aβ neu-

To test whether suppressing amylin secretion reduces AD-related neu-

ritic plaques, immunostaining showed the presence of amylin in small

rologic deficits, we crossed APP/PS1 rats with amylin knockout rats

proteinaceous fragments (Figures 1F and 1G; arrows). Confocal micro-

(AKO rats) to generate APP/PS1/AKO rats that lack the amylin gene.

scopic analysis of areas containing amylin-positive neurons revealed

AKO rats were previously characterized.7 Rats from the F3 generation

no overlap between the immunoreactivity signals for amylin and p-tau

were used in these experiments to ensure the homozygosity of AKO

(Figure S2A-S2C in supporting information) suggesting distinct amylin

genotype in the APP/PS1/AKO model.

and tau pathologies.
To test whether mixed amylin–Aβ plaques have biochemical characteristics of amyloid, brain slices were triple-stained with Thioflavin

2.2.3
Immunochemical detection of human versus
rat amylin

S and anti-amylin and anti-Aβ antibodies. Confocal microscopy analysis identified Thioflavin S–positive areas within the Aβ deposits (Figure
S2D) and in the amylin cores of mixed amylin-Aβ plaques (Figure 1N-Q).

Because homozygous HIP and APP/PS1/HIP rats have increased mor-

Amylin amyloid plaques have similar structures to those formed in sAD

tality rates, we used heterozygous rats that express both human and

(Figure S2E).

rat amylin. ELISA and anti-amylin antibody sensitivities/affinities are

In sAD brains, amylin was identified within the arteriole wall, as

higher for rat versus human amylin (technical evaluation in Appendix

part of cerebral amyloid angiopathy (CAA).3,4 Post mortem histological

A).

reports included comorbid CAA in many fAD brains from this cohort
(Table B.4). Histological evidence of cerebral small vessel disease was
reported also in CU brains (Table B.4). We tested the association

3

RESULTS

of brain amylin accumulation with blood-brain barrier (BBB) leak by
assessing the brain uptake of immunoglobulins (IgG). Analysis of anti-

3.1
Circulating amylin cross-seeds with Aβ in
brains of PS1 and APP mutation carriers

IgG staining in brain sections revealed variable levels of compromised
BBB (Figure S3 in supporting information) in both fAD and CU brain
groups. IHC analyses of serial sections for amylin, amylin–Aβ cross-

To test the hypothesis (Figure 1A) that amylin secreted from the pan-

seeding, and Congo red staining (Figure 1R-U) suggest that amylin is

creas interacts with fAD pathology, brain tissue from fAD mutation car-

part of CAA. This was further confirmed by confocal microscopy analy-

riers and CU individuals were analyzed using ELISA, IHC, and confocal

sis of brain sections triple-stained for amylin, Aβ, and α-smooth muscle

microscopy. Amylin ELISA revealed that brains of PS1 mutation carri-

cell actin (Figure 1V-Y). Brain amylin pathology is summarized in Table

ers had higher amylin levels compared to CU individuals (Figure 1B).

B.5.

Increased brain amylin concentrations were associated with greater

Analyses of the association of common and rare amylin gene vari-

Aβ42 levels in PS1 versus CU brains (ELISA; Figure 1C). A nonsignificant

ants with the risk of developing AD revealed no statistically signifi-

increased brain accumulation of amylin was also identified in APP ver-

cant differences (Table B6). Taken together, our results indicate that

sus CU brains (P = 0.09; Figure 1B), which is similar to the tendency for

circulating amyloid-forming amylin secreted from the pancreas inter-

higher Aβ42 in this group (P = 0.07; Figure 1C). Overall, increased brain

acts with fAD pathology through mechanisms that are not linked to a

amylin levels correlated strongly (R2 = 0.40, P < 0.01) with increased

genetic predisposition and may involve amylin as a part of CAA.

brain Aβ42 levels in fAD (Figure 1D), whereas the amylin–Aβ relationship was variable in CU brains (Figure 1E).
IHC co-staining with anti-amylin and anti-Aβ antibodies in fAD
brain sections detected distinct amylin and Aβ plaques and mixed

3.2
High CSF amylin levels are associated with
decreased CSF Aβ42 levels in early AD

amylin–Aβ plaques (Figure 1F-M). Some plaques stained positive
for amylin adjacent to Aβ deposition (Figures 1H and 1I), had lay-

The order of biological changes in fAD begins with deposition of

ered amylin–Aβ compositions with amylin-positive cores (Figure 1J-L)

amyloid, followed by neurodegenerative changes (assessed from CSF

or formed intercalated amylin–Aβ deposits as shown in Figure 1M.

biomarkers) and cognitive decline.17 To test whether amylin homeosta-

For deconvolution and analysis of amylin immunoreactivity inten-

sis in the central nervous system may change in early sAD, we investi-

sity signals on IHC images, pancreatic tissue from a patient with

gated the relationships between CSF amylin and CSF Aβ42 , a validated

type 2 diabetes served as positive control for amylin deposition

AD biomarker,2 in CU, MCI, and sAD dementia CSF samples. The aver-

(Figure S1A in supporting information). The IHC analysis detected

age CSF levels of both amylin and Aβ42 are associated with the cogni-

amylin in about one third of the plaques in fAD brains (Figure

tive status (Figure 2A-B). Decreased CSF Aβ42 levels correlated with

S1B). CU brains have sporadic amylin deposits (Figure S1C); how-

decreased CSF amylin levels in sAD (Figure 2C). In MCI, however, CSF

ever, amylin–Aβ cross-seeding is lower in CU versus fAD brains

amylin and Aβ42 levels were inversely correlated, with lower Aβ42 lev-

(Figure 1C).

els being associated with higher amylin levels (Figure 2D). Both CSF
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F I G U R E 1 Brain amylin–amyloid beta (Aβ) relationship in PSEN1 and APP mutation carriers. A, Schematic amylin–Aβ cross-seeding
hypothesis. B-E, Amylin and Aβ42 levels and the relationship between amylin and Aβ42 concentrations in temporal cortex specimens from PS1 and
APP mutation carriers (n = 11 and n = 7, respectively) and cognitively unaffected individuals (CU; n = 12). F-M, Representative images of
immunohistochemistry analysis using anti-amylin (brown) and anti-Aβ (green) antibodies on temporal cortex slices from familial Alzheimer’s
disease (fAD) brains. Amylin deposition in neurons (F, G; arrowheads) or forming homogenous plaques (F, G; arrows; H, I) and amylin–Aβ plaques
(J-M) are shown. N-Q, Confocal microscopic analysis of a fAD brain section triple stained with Thioflavin S (ThioS, green; N), anti-amylin antibody
(red; O), and anti-Aβ antibody (magenta; P). R-U, representative images of consecutive fAD brain sections stained with Congo red (R), anti-Aβ (S),
anti-amylin (T), or a combination of anti-amylin (brown) and anti-Aβ (green; U) antibodies. V-Y, Confocal microscopic analysis of a fAD brain section
triple stained with anti-amylin antibody (green; V), anti-Aβ antibody (red; W) and anti-α smooth muscle cell (SMC) actin antibody (blue; X). Type of
PS1 or APP mutation is labeled on each image; three sections/brain, n = 27 fAD brains and n = 27 CU brains. Scale bars, 50 μm (F-M, R-U), 10 μm
(N-Q) and (V-Y). Data are means ± standard error of the mean; P ≤ 0.01 **, P ≤ 0.0001 ****; one-way analysis of variance with Dunnett’s multiple
comparisons test (B, C); correlation analysis (D, E)

amylin and Aβ42 levels were highly variable in the CU individuals (Fig-

shown in Figure S4A-S4C in supporting information. Study design and

ure 2E).

study time points are described in Figure 3A-C.

These results suggest that increases in CSF amylin and decreases in

Although APP/PS1/HIP and HIP rats overexpress human amylin

CSF Aβ42 levels may be characteristic of early cognitive change in the

throughout their lives, their plasma levels of amylin (combined rat and

MCI stage of sAD, which needs to be further evaluated in a larger sam-

human amylin) increase with aging (> 12 months of age), whereas

ple with longitudinal characterization of the cohort.

there is no significant change of plasma levels of amylin (rat amylin
only) in APP/PS1 and WT littermates (Figures 3D and 3E). Plasma from
APP/PS1/HIP rats had increased amylin immunoreactivity intensity

3.3
Genetically suppressed amylin secretion in
APP/PS1 rats protects against AD effects

signals at high molecular weight bands (> 3.9 kDa; monomeric amylin)
compared to plasma from APP/PS1 littermates (Figure S5 in supporting information). The results are consistent with previous reports in

To address the potential for altering AD-related pathology/symptoms

HIP versus WT rats7,15,18 and reflect the constructive validity of the

through modulation of the blood amylin level, we genetically manipu-

human amylin-expressing rats. We interpret the presence of aggre-

lated amylin secretion in APP/PS1 and non-APP/PS1 rats by pancreatic

gated amylin in the systemic circulation as a possible sign of amylin

overexpression of human amylin (3-fold) or amylin gene deletion. Rep-

dyshomeostasis that may be triggered by different conditions, includ-

resentative genotyping results for newly generated transgenic rats are

ing amylin hypersecretion (common in prediabetes).7 APP/PS1/HIP
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F I G U R E 2 Cerebrospinal fluid (CSF) amylin–amyloid beta (Aβ)42 relationship in Alzheimer’s disease (AD), mild cognitive impairment (MCI),
and cognitively unaffected (CU) humans. A, B, Levels of CSF amylin (A) and CSF Aβ42 (B) in patients with sporadic AD (sAD, n = 28); individuals with
MCI (n = 70), and in CU individuals (n = 117). C-E, Correlation analysis of CSF amylin levels versus CSF Aβ42 levels in patients from (A, B). Data are
presented as box and whisker plot (A, B) and as individual values (C-E); P ≤ 0.05 *, P ≤ 0.01 **, P ≤ 0.001 ***, P ≤ 0.0001 ****; two-tailed, unpaired t
test (A, B); correlation analysis (C-E)

rats with high plasma levels of amylin (combined rat and human amylin)

in the absence of genetic determinants of AD pathology in HIP rats; and

had greater behavior deficits (Figure 3D and Figure S6A-S6C in sup-

(3) suppression of amylin secretion provides a sustained protection lon-

porting information), which worsened at a higher rate with aging than

gitudinally against recognition memory deficits in APP/PS1/AKO rats,

in APP/PS1 littermates expressing only rat amylin (Figure 3F). Sim-

compared to APP/PS1 rats.

ilarly, cognitive performance declined faster in aged HIP rats with
high plasma amylin levels (combined rat and human amylin) than in
WT littermates (Figures 3E and 3G and S6D-S6F). The neurological
score-plasma amylin relationship in HIP rats versus WT littermates

3.4
High blood amylin disrupts CSF–brain Aβ
exchange by amylin–Aβ cross-seeding in brain

(Figure 3E) suggests that high blood amylin levels affect neurological
score in the absence of genetic determinants of AD pathology.

Next, we tested amylin–Aβ interaction in aged APP/PS1/HIP and

The Novel Object Recognition (NOR) test in HIP rats (Figure S6D in

APP/PS1 littermates using IHC co-staining with anti-amylin and anti-

supporting information) suggests that amylin dyshomeostasis impairs

Aβ antibodies in brain slices (Figure 4A-E). The density of plaques

short-term memory with age in the absence of AD-like pathology. We

(amylin, Aβ, and amylin–Aβ plaques) was higher in 16-month-old

therefore tested whether suppressed amylin expression in APP/PS1

APP/PS1/HIP rat brains compared to controls (Figure 4F). Amylin

rats alters the results of the NOR task. APP/PS1 with the amylin gene

formed the protein core of Aβ plaques in both groups (Figure 4A-D);

deleted (APP/PS1/AKO rats) had lower plasma amylin and less severe

however, surface area covered by mixed amylin–Aβ deposits was

memory retention deficits at age 16 months compared to APP/PS1 lit-

higher in APP/PS1/HIP brains compared to that in APP/PS1 rat brains

termates (Figure 3H-J).

(Figures 4G and 4H). Non-APP/PS1 rats expressing human amylin (ie,

Our results suggest the following: (1) rats that are prone to develop

the HIP rats) had brain amylin deposition in the absence of AD muta-

mixed amylin–Aβ pathology have greater neurological deficits com-

tions (Figure S7A-S7B in supporting information). In contrast, WT rats

pared to APP/PS1 rats; (2) high blood amylin levels affect brain function

had no cerebral amylin plaques suggesting that rat amylin does not
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F I G U R E 3 Behavior deficits in APP/PS1 and non-APP/PS1 rats with genetically manipulated amylin secretion. A-C, Schematic summary of rat
models generated for this study and time points of behavior and molecular analyses. Genetic manipulation of circulating amylin was performed in
rats with and without Alzheimer’s disease (AD)-like pathology through transgenic expression of human amylin in the pancreas (red color code, A)
and by deletion of the amylin gene (light blue color code, B). The time points for behavioral studies were chosen based on previous reports that
amylin dyshomeostasis develops at ≈12 months of age in human amylin expressing rats7,15 and that amyloid beta (Aβ) pathology is developed in
APP/PS1 rats at about 16 months of age16 (C). D-G, Longitudinal neurological scores of cognitive function (assessed from Novel Object Recognition
and water maze performance tests) versus plasma amylin levels (both rat and human amylin; D, E) and versus age (F, G) in APP/PS1/HIP versus
APP/PS1 rats, and HIP versus wild-type (WT) rats (n = 10 rats/group). Data for individual tests are shown in Figure S6 in supporting information. H,
Plasma amylin levels in APP/PS1 rats versus APP/PS1 rats with suppressed amylin expression (APP/PS1/AKO rats) at 16 months of age. I, Novel
object recognition in APP/PS1 rats versus APP/PS1/AKO rats at 8, 12, and 16 months of age (n = 10 rats/group). J, Longitudinal neurological scores
of cognitive function in APP/PS1 versus APP/PS1/AKO rats (n = 10 rats/group). Data are means ± standard error of the mean. P ≤ 0.05 *, P ≤ 0.01
**, *, P ≤ 0.001 ***; correlation analysis (D, E); two-way analysis of variance with Sidak post hoc (F, G, J); two-tailed, unpaired t test (H, I)

form cerebral plaques in non-APP/PS1 rats that express only rat amylin.
In addition to amylin-core Aβ plaques, APP/PS1/HIP rat brains had

3.5
Suppressed amylin secretion decreases
amyloid density in plaques

amylin accumulation in neuronal soma (Figure 4E) mirroring our findings in fAD brains (Figure 1). Cerebral vascular deposition of amylin was

Cross-seeding between rat amylin and Aβ in APP/PS1 rat brains

identified in APP/PS1/HIP and HIP rats, but not APP/PS1 and WT rats

was unanticipated, because rodent amylin does not form amyloid.9

(Figure S7C-S7F), indicating a possible relationship between high blood

In contrast to the human brain (which lacks amylin mRNA3 ), some

amylin levels and cerebral vascular amylin deposition. Pancreatic tissue

rodent brain cells appear to secrete amylin10 that may promote

from rats in all groups were used as controls for amylin immunoreactiv-

direct amylin–Aβ interaction in APP/PS1 rats. We therefore tested

ity signals in the brains (Figure S8A-S8E in supporting information).

whether genetically suppressed amylin secretion in APP/PS1 rats

Higher plasma levels of amylin (combined human and rat amylin)

is associated with decreased cerebral amylin–Aβ plaque formation.

in APP/PS1/HIP versus APP/PS1 rats are associated with lower CSF

Essentially, APP/PS1/AKO rats with the amylin gene deleted lacked

Aβ levels (Figure 4I) and more cerebral plaques (Figure 4F). Amylin

amylin–Aβ cross-seeding in the brains, whereas APP/PS1 littermates

secreted from the pancreas accumulated in the brain (Figure 4J) and

had amylin-core Aβ plaques (CP) in brain sections (Figure 5A-G).

cross-seeded with Aβ (Figure 4G) without significant change of the CSF

Decreased amylin–Aβ cross-seeding in APP/PS1/AKO rat brains

concentration of amylin (combined human and rat amylin; Figure 4K).

correlated with lower amylin immunoreactivity intensity signal

These results suggest that increased circulating amylin levels may

in pancreatic tissues (Figure S8E), plasma (Figure 3H), and brain

alter CSF–brain Aβ exchange through amylin–Aβ cross-seeding in the

homogenates (Figure 5H) from these rats, compared to APP/PS1

brain.

rats.
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F I G U R E 4 Amylin–amyloid beta (Aβ) cross-seeding and impaired cerebrospinal fluid (CSF)–brain Aβ exchange by high blood amylin levels
(both rat and human amylin) in APP/PS1 rats. A-E, Representative immunohistological images of co-staining with anti-amylin (brown) and anti-Aβ
(green) antibodies in brain sections from 16-month-old APP/PS1/HIP rats (A, C, E) and APP/PS1 rats (B, D; n = 5 rats/group). Amylin–Aβ plaques
(A-D) and amylin depositions within neurons (E) are shown. F, Analysis of total plaques including Aβ plaque, amylin plaque, and amylin-core Aβ
plaque depositions in APP/PS1 and APP/PS1/HIP rat brains, assessed from immunohistological images (n = 5 rats/group; data were normalized to
total imaging area). G, H, Relative distribution of amylin, Aβ, and amylin–Aβ in plaques in the gray matter of APP/PS1/HIP rat brains (G; n = 5) and
APP/PS1 rat brains (H; n = 5). I-K, CSF total Aβ (I; n = 6 rats/group), brain amylin (Triton-soluble fractions of tissue homogenate; n = 5 rats/group; J),
and CSF amylin (K; n = 6 rats/group) levels in APP/PS1/HIP versus APP/PS1 rats at 16 months of age. Scale bars, 200 μm (A, B), 50 μm (C-E). Data
are means ± standard error of the mean; P ≤ 0.05 *, P ≤ 0.01 **, P ≤ 0.001 ***; two-tailed, unpaired t test

F I G U R E 5 Decreased brain amylin amyloid-core plaques in APP/PS1 rats with genetically suppressed amylin secretion. A-F, Representative
images of immunostaining for amylin (brown) and amyloid beta (Aβ) (green) in brain tissues from 16-month-old APP/PS1/AKO rats (A-C) and
APP/PS1 littermates (D-F). Arrows indicate amylin-core Aβ plaques (CP). G, Counts of amylin-core Aβ plaques in APP/PS1 and APP/PS1/AKO rat
brains assessed from immunohistological images (n = 5 rats/group; data were normalized to total imaging area). H, I, Amylin and Aβ levels in brain
homogenates from 16-month-old APP/PS1/AKO rats and APP/PS1 littermates. J, Counts of Aβ plaques in the same APP/PS1 and APP/PS1/AKO
rat brains as in (G; n = 5 rats/group). Scale bars, 50 μm (A, B, D, E), 200 μm (C, F). Data are means ± standard error of the mean. P ≤ 0.05 *; P ≤ 0.01
**; two-tailed, unpaired t test
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F I G U R E 6 Circulating aggregated amylin cross-seeds with brain amyloid beta (Aβ) in young APP/PS1 rats. A, Experimental protocol for
intravenous amylin infusion in rats. B, Plasma amylin levels in APP/PS1 rats intravenously infused with human amylin and age matched APP/PS1
control rats at baseline and after injections (n = 5 rats/group). C, D, Immunohistological analysis with anti-amylin (brown) and anti-Aβ (green)
antibodies showing amylin-Aβ plaques (C; arrow) and amylin accumulation in neurons (D; circles) of APP/PS1 rats intravenously infused with
human amylin and age-matched APP/PS1 control rats (n = 3 rats/group). E, Western blot analysis of amylin and Aβ levels in the brain homogenate
extracted using phosphate-buffered saline or sodium dodecyl sulfate from APP/PS1 rats intravenously infused with human amylin and
age-matched APP/PS1 control rats (n = 3-4 rats/group). F, Schematic summary of the results. Circulating aggregated amylin affects brain and
cerebrospinal fluid (CSF) Aβ levels via brain amylin accumulation and amylin-Aβ cross-seeding. Amylin gene deletion in APP/PS1 rats blocks amylin
accumulation in the brain and amylin–Aβ cross-seeding, providing protection against AD-associated effects. Scale bars, 50 μm (C, D). Data are
means ± standard error of the mean; two-tailed, paired t test (B), P ≤ 0.05 *; two-tailed, unpaired t test (E)

It is worth noting that lack of endogenous rat amylin secretion in

pre-aggregated human amylin (Figure 6A; the schematic schedule of

APP/PS1/AKO rats appears to not increase brain Aβ concentration

the treatment). Amylin was infused for 2 months at a dose that only

(measured by total Aβ ELISA) in the APP/PS1/AKO rat brains, com-

slightly elevated the plasma amylin level (Figure 6B). The aggregation

pared to APP/PS1 littermates (Figure 5I). The extent of Aβ pathol-

status/size distribution of injected amylin is shown in Figure S10 in

ogy was similar in APP/PS1 and APP/PS1/AKO rats (Figure 5J). Fur-

supporting information. At the conclusion of the infusion regimen,

thermore, western blot analysis of brain homogenates from APP/PS1

amylin-core Aβ plaques were detected in treated (Figure 6C) but not

versus APP/PS1/AKO rat brains suggests that suppressed circulating

in untreated rats. Brains of APP/PS1 rats intravenously infused with

amylin does not increase soluble Aβ levels in the brain (Figure S9 in sup-

human amylin also showed neuronal amylin deposition (Figure 6D),

porting information).

consistent with our findings in APP/PS1/HIP rats (Figure 4E) and
human fAD brains (Figure 1F-G), and higher soluble amylin and Aβ
levels by western blot analysis of brain homogenates (Figure 6E and

3.6
Circulating aggregated amylin accelerates
amylin–Aβ cross-seeding in the brain

Figure S11 in supporting information).
The results support the hypothesis that circulating aggregated
amylin (amyloid-forming) has a great effect on the cerebral plaque

Greater pathological processes in brains of aged APP/PS1/HIP versus

structure by promoting amylin–Aβ cross-seeding.

APP/PS1 rats were associated with circulating aggregated amylin (Figure S5), and this was also the case in plasma from aged HIP versus WT
rats.7,15,18 To assess the impact of circulating aggregated human amylin

4

DISCUSSION

(amyloid forming) on early AD pathological processes, young APP/PS1
rats (age 7 months), studied before the development of Aβ pathology

This study shows that circulating amyloid-forming amylin secreted

(which occurs at age ≈16 months), were injected intravenously with

by the pancreas cross-seeded with Aβ in brain parenchyma and blood
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vessel walls in PSEN1 and APP mutation carriers. Increases in CSF

There are limitations to our study of fAD brain specimens and

amylin and decreases in CSF Aβ42 levels appeared in the setting

human CSF. We were not able to track possible glucose dysregula-

of early cognitive change in the MCI stage of sAD. In APP/PS1

tion in patients. Neither effects of anti-AD treatments nor specific

rats, genetically suppressed amylin secretion protected against AD

forms of anti-depressant drugs given to individual patients, which

effects, whereas hypersecretion of human amylin accelerated AD-like

may affect pancreatic function including amylin and insulin secretion,

pathology through (at least in part) circulating aggregated amylin.

were available. The CSF amylin–Aβ42 relationship needs to be fur-

At the molecular level, circulating aggregated amylin correlated with

ther tested in a larger sample with longitudinal characterization of the

disrupted CSF–brain Aβ exchange and amylin–Aβ cross-seeding in

cohort.

the brain. Intravenously infused aggregated human amylin induced

In conclusion, finding amylin–Aβ cross-seeding in fAD mutation car-

amylin–Aβ cross-seeding in young APP/PS1 rats before the devel-

riers is of interest because: (1) a role of pancreatic amylin in familial AD

opment of Aβ pathology. These results (summarized in Figure 6F)

was previously unknown, (2) there is accumulating evidence showing

demonstrate a role of circulating aggregated amylin in early AD and

brain amylin dyshomeostasis in the much more prevalent sporadic form

suggest that restoring amylin homeostasis may reduce AD pathology.

of AD, and (3) development of anti-amylin drugs may improve the lives

Amylin dysregulation contributes to type 2 diabetes.9,19 Aβ crossseeds with amylin in the pancreatic

islets5

of fAD mutation carriers and slow the progression of sporadic AD.

suggesting that AD-

related pathological processes may affect β-cell function. Because the
hypothalamus regulates pancreatic β-cell function20 and is affected
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